Sugi Predict

Sugi Predict / Compounds / SCHEMBL199239

SCHEMBL199239

SCHEMBL199239

COC(=O)c1ccc(O)c(F)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 5/20 0.69
▸ CA2 P00918 5/20 0.69
▸ CA12 O43570 4/20 0.69
▸ CA7 P43166 4/20 0.69
▸ CA9 Q16790 4/20 0.69
▸ CA14 Q9ULX7 4/20 0.69
▸ XDH P47989 2/20 0.69
▸ KDM4E B2RXH2 4/20 0.61
▸ HSD17B10 Q99714 4/20 0.61
▸ LMNA P02545 3/20 0.61
▸ ALDH1A1 P00352 3/20 0.61
▸ HPGD P15428 3/20 0.61
▸ MAPT P10636 2/20 0.61
▸ TP53 P04637 2/20 0.61
▸ ALOX15 P16050 2/20 0.61
▸ ALOX12 P18054 2/20 0.61
▸ MEN1 O00255 1/20 0.61
▸ HTT P42858 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3468564 0.90 CA1 (0.56) CA1CA2CA12CA7CA9
SCHEMBL29433261 0.85 CA1 (0.69) CA1CA2CA12CA7CA9
SCHEMBL851097 0.85 CA1 (0.69) CA1CA2CA12CA7CA9
SCHEMBL29664708 0.84 CES2 (0.59) CA1CA2CA12CA7CA9
SCHEMBL383936 0.84 CES2 (0.59) CA1CA2CA12CA7CA9
SCHEMBL14012582 0.84 CES2 (0.59) CA1CA2CA12CA7CA9
Methyl Protocatechuate SCHEMBL38624 0.82 CA1 (1.00) CA1CA2CA12CA7CA9
Methyl Protocatechuate SCHEMBL29360855 0.82 CA1 (1.00) CA1CA2CA12CA7CA9
SCHEMBL16494260 0.81 XDH (0.59) CA1CA2CA12CA7CA9
SCHEMBL1495863 0.81 HDAC1 (0.62) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138990-A1 TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS INC (US) 2026-05-21 — — US disclosed
US-12624028-B2 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2026-05-12 — — US disclosed
WO-2026087635-A1 DIHYDRO BENZOXAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 — — WO disclosed
EP-4702026-A1 TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF Aeovian Pharmaceuticals, Inc. (US) 2026-03-04 — — EP disclosed
WO-2025262003-A1 DIHYDRO BENZOXAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2025-12-26 — — WO disclosed
EP-4665339-A1 INHIBITING ALPHA V BETA 8 INTEGRIN Morphic Therapeutic, Inc. (US) 2025-12-24 — — EP disclosed
US-20250304603-A1 OXABOROLE ESTERS AND USES THEREOF ANACOR PHARMACEUTICALS INC (US) 2025-10-02 — — US disclosed
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. 2025-05-22 — — US disclosed
EP-4552695-A2 TYROSINE KINASES INHIBITORS AND USES THEREOF Great Novel Therapeutics Biotech & Medicals Corporation (TW) 2025-05-14 — — EP disclosed
CN-119841776-A Tyrosine kinase inhibitors and uses thereof 华上生技医药股份有限公司 2025-04-18 — — CN disclosed
US-5132041-A Liquid crystal compounds having ether tail moiety POLAROID CORPORATION (US) 1992-07-21 — — US disclosed
EP-0137242-B1 (SUBSTITUTED) PHENYL-ALIPHATIC-ISOXAZOLES USEFUL AS ANTIVIRAL AGENTS AND PREPARATION THEREOF STERLING WINTHROP INC. (US) 1992-05-13 — — EP disclosed
EP-0418922-A2 Mesomorphic compound, liquid crystal composition containing same and liquid crystal device using same CANON KABUSHIKI KAISHA (JP) 1991-03-27 — — EP disclosed
US-5002960-A Viricides for combating picornaviruses STERLING DRUG, INC. (US) 1991-03-26 — — US disclosed
US-4939267-A Viricides STERLING DRUG INC. (US) 1990-07-03 — — US disclosed
US-4857227-A Liquid crystal mixtures having widened smectic temperature range POLAROID CORPORATION PATENT DEPARTMENT (US) 1989-08-15 — — US disclosed
US-4843087-A OXAZOLINYL COMPOUNDS; RHINOVIRUSES AND PICORNAVIRUSES STERLING DRUG INC. (US) 1989-06-27 — — US disclosed
EP-0258578-A2 Liquid crystal compounds having ether tail moiety POLAROID CORPORATION (US) 1988-03-09 — — EP disclosed
EP-0256303-A2 Liquid crystal compounds having fluorine-containing core POLAROID CORPORATION (US) 1988-02-24 — — EP disclosed
EP-0137242-A2 (Substituted) Phenyl-aliphatic-isoxazoles useful as antiviral agents and preparation thereof STERLING WINTHROP INC. (US) 1985-04-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138990-A1 TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF CD38, BCL9, BCL6B CA1 789/4885CA2 187/4885CA12 75/4885
US-20250304603-A1 OXABOROLE ESTERS AND USES THEREOF OXA1L, HSD17B12, OXER1 CA1 3605/4885CA2 2852/4885CA12 1813/4885
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF CBLB, CBL, CBLC CA1 4855/4885CA2 4707/4885CA12 4823/4885
US-12624028-B2 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) SERPINA2, SERPINC1, SERPINH1 CA1 3938/4885CA2 3093/4885CA12 4109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.